Published in Lancet Infect Dis on September 01, 2007
High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol (2011) 3.11
IL-23 and IL-17 in tuberculosis. Cytokine (2008) 2.35
The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models. Nat Rev Microbiol (2010) 2.22
Antibiotic exposure and IBD development among children: a population-based cohort study. Pediatrics (2012) 2.04
IBD-what role do Proteobacteria play? Nat Rev Gastroenterol Hepatol (2012) 2.03
Non-tuberculous mycobacteria in TB-endemic countries: are we neglecting the danger? PLoS Negl Trop Dis (2010) 2.03
Mycobacterium avium subspecies paratuberculosis infection in cases of irritable bowel syndrome and comparison with Crohn's disease and Johne's disease: common neural and immune pathogenicities. J Clin Microbiol (2007) 1.54
Environmental risk factors for inflammatory bowel disease. Gastroenterol Hepatol (N Y) (2010) 1.48
Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn's disease. J Gastroenterol (2012) 1.31
The role of bacteria and pattern-recognition receptors in Crohn's disease. Nat Rev Gastroenterol Hepatol (2011) 1.27
Crohn disease: a current perspective on genetics, autophagy and immunity. Autophagy (2011) 1.26
Occurrence of Mycobacterium avium subspecies paratuberculosis across host species and European countries with evidence for transmission between wildlife and domestic ruminants. BMC Microbiol (2009) 1.20
Insertion and deletion events that define the pathogen Mycobacterium avium subsp. paratuberculosis. J Bacteriol (2008) 1.18
Mycobacterium avium subspecies paratuberculosis, Crohn's disease and the Doomsday scenario. Gut Pathog (2009) 1.17
Discovery of stable and variable differences in the Mycobacterium avium subsp. paratuberculosis type I, II, and III genomes by pan-genome microarray analysis. Appl Environ Microbiol (2008) 1.15
The role of bacteria in the pathogenesis of inflammatory bowel disease. Gut Liver (2010) 1.12
Crohn's disease: an immune deficiency state. Clin Rev Allergy Immunol (2010) 1.10
Role of commensal gut bacteria in inflammatory bowel diseases. Gut Microbes (2012) 1.08
Environment and the inflammatory bowel diseases. Can J Gastroenterol (2013) 1.07
Mycobacterium avium subspecies paratuberculosis and its relationship with Crohn's disease. World J Gastroenterol (2009) 1.06
Intestinal Behçet's Disease: A True Inflammatory Bowel Disease or Merely an Intestinal Complication of Systemic Vasculitis? Yonsei Med J (2016) 1.03
Where are all the Mycobacterium avium subspecies paratuberculosis in patients with Crohn's disease? PLoS Pathog (2009) 1.02
The gut microbiota and inflammatory bowel disease. Semin Immunopathol (2014) 1.01
Isolation of Mycobacterium avium subspecies paratuberculosis reactive CD4 T cells from intestinal biopsies of Crohn's disease patients. PLoS One (2009) 0.97
Importance of nutrition in inflammatory bowel disease. World J Gastroenterol (2009) 0.96
Detection of Mycobacterium avium subsp. paratuberculosis in drinking water and biofilms by quantitative PCR. Appl Environ Microbiol (2010) 0.95
Fate of Mycobacterium avium subsp. paratuberculosis after application of contaminated dairy cattle manure to agricultural soils. Appl Environ Microbiol (2011) 0.94
State-of-the-art of irritable bowel syndrome and inflammatory bowel disease research in 2008. World J Gastroenterol (2008) 0.94
Ulcerative colitis and Crohn's disease: is Mycobacterium avium subspecies paratuberculosis the common villain? Gut Pathog (2010) 0.94
High prevalence of viable Mycobacterium avium subspecies paratuberculosis in Crohn's disease. World J Gastroenterol (2010) 0.93
Mycobacterium avium subsp. paratuberculosis in an Italian cohort of type 1 diabetes pediatric patients. Clin Dev Immunol (2012) 0.91
Sequence polymorphisms in a surface PPE protein distinguish types I, II, and III of Mycobacterium avium subsp. paratuberculosis. J Clin Microbiol (2008) 0.90
Fecal detection of Mycobacterium avium paratuberculosis using the IS900 DNA sequence in Crohn's disease and ulcerative colitis patients and healthy subjects. Dig Dis Sci (2011) 0.89
A novel multi-antigen virally vectored vaccine against Mycobacterium avium subspecies paratuberculosis. PLoS One (2007) 0.88
Ovine paratuberculosis: a seroprevalence study in dairy flocks reared in the marche region, Italy. Vet Med Int (2011) 0.87
Anti-inflammatory and antiapoptotic responses to infection: a common denominator of human and bovine macrophages infected with Mycobacterium avium subsp. paratuberculosis. Biomed Res Int (2013) 0.87
Matrix metalloproteinases in inflammatory bowel disease: an update. Mediators Inflamm (2015) 0.87
A breakthrough in probiotics: Clostridium butyricum regulates gut homeostasis and anti-inflammatory response in inflammatory bowel disease. J Gastroenterol (2015) 0.86
The contribution of natural selection to present-day susceptibility to chronic inflammatory and autoimmune disease. Curr Opin Immunol (2014) 0.86
Immunogenicity and reactivity of novel Mycobacterium avium subsp. paratuberculosis PPE MAP1152 and conserved MAP1156 proteins with sera from experimentally and naturally infected animals. Clin Vaccine Immunol (2010) 0.85
Mycobacterium avium subsp. paratuberculosis lipophilic antigen causes Crohn's disease-type necrotizing colitis in Mice. Springerplus (2012) 0.84
Genetic structure of Mycobacterium avium subsp. paratuberculosis population in cattle herds in Quebec as revealed by using a combination of multilocus genomic analyses. J Clin Microbiol (2014) 0.84
Mycobacterium avium subspecies Paratuberculosis and Crohn's regional ileitis: how strong is association? J Lab Physicians (2011) 0.84
Infliximab therapy increases the frequency of circulating CD16(+) monocytes and modifies macrophage cytokine response to bacterial infection. Clin Exp Immunol (2014) 0.83
Genetic diversity of Mycobacterium avium isolates recovered from clinical samples and from the environment: molecular characterization for diagnostic purposes. J Clin Microbiol (2008) 0.83
NOD2 and ATG16L1 polymorphisms affect monocyte responses in Crohn's disease. World J Gastroenterol (2011) 0.83
Mycobacterium avium subspecies paratuberculosis in the etiology of Crohn's disease, cause or epiphenomenon? World J Gastroenterol (2014) 0.83
The Association of Mycobacterium avium subsp. paratuberculosis with Inflammatory Bowel Disease. PLoS One (2016) 0.82
A Missense LRRK2 Variant Is a Risk Factor for Excessive Inflammatory Responses in Leprosy. PLoS Negl Trop Dis (2016) 0.82
Genomic comparison of PE and PPE genes in the Mycobacterium avium complex. J Clin Microbiol (2009) 0.82
Genetic evidence supporting the association of protease and protease inhibitor genes with inflammatory bowel disease: a systematic review. PLoS One (2011) 0.82
The Single Intradermal Cervical Comparative Test Interferes with Johne's Disease ELISA Diagnostics. Front Immunol (2014) 0.82
The epidemiology and risk factors of inflammatory bowel disease. Int J Clin Exp Med (2015) 0.82
Gut bacterial profile in patients newly diagnosed with treatment-naïve Crohn's disease. Clin Exp Gastroenterol (2012) 0.81
Presence of intestinal Mycobacterium avium subspecies paratuberculosis (MAP) DNA is not associated with altered MMP expression in ulcerative colitis. BMC Gastroenterol (2011) 0.81
Serum antibodies to Mycobacterium avium subspecies paratuberculosis combined with anti-Saccharomyces cerevisiae antibodies in Crohn's disease patients: prevalence and diagnostic role. Dig Dis Sci (2011) 0.81
Is There a Link Between H. Pylori and the Epidemiology of Crohn's Disease? Dig Dis Sci (2017) 0.81
Metabolomic profiling in cattle experimentally infected with Mycobacterium avium subsp. paratuberculosis. PLoS One (2014) 0.80
Specific IgG response against Mycobacterium avium paratuberculosis in children and adults with Crohn's disease. PLoS One (2013) 0.80
Estimated prevalence of caprine paratuberculosis in boer goat herds in missouri, USA. Vet Med Int (2012) 0.80
Assessment of Dietzia subsp. C79793-74 for treatment of cattle with evidence of paratuberculosis. Virulence (2010) 0.80
Influence of environmental factors in the development of inflammatory bowel diseases. World J Gastrointest Pharmacol Ther (2016) 0.80
Systemic and mucosal immune reactivity upon Mycobacterium avium ssp. paratuberculosis infection in mice. PLoS One (2014) 0.79
A 60-day probiotic protocol with Dietzia subsp. C79793-74 prevents development of Johne's disease parameters after in utero and/or neonatal MAP infection. Virulence (2011) 0.79
Resolution of Crohn's disease and complex regional pain syndrome following treatment of paratuberculosis. World J Gastroenterol (2015) 0.79
The Mycobacterium avium ssp. paratuberculosis specific mptD gene is required for maintenance of the metabolic homeostasis necessary for full virulence in mouse infections. Front Cell Infect Microbiol (2014) 0.79
Individuality, phenotypic differentiation, dormancy and 'persistence' in culturable bacterial systems: commonalities shared by environmental, laboratory, and clinical microbiology. F1000Res (2015) 0.79
M. paratuberculosis Heat Shock Protein 65 and Human Diseases: Bridging Infection and Autoimmunity. Autoimmune Dis (2012) 0.79
Mycobacterium avium Subspecies paratuberculosis: Human Exposure through Environmental and Domestic Aerosols. Pathogens (2014) 0.78
Microbiomes of unreactive and pathologically altered ileocecal lymph nodes of slaughter pigs. Appl Environ Microbiol (2013) 0.78
Prevalence of Mycobacterium avium subsp. paratuberculosis and Escherichia coli in blood samples from patients with inflammatory bowel disease. Med Microbiol Immunol (2015) 0.78
Three-dimensional in vitro models of granuloma to study bacteria-host interactions, drug-susceptibility, and resuscitation of dormant mycobacteria. Biomed Res Int (2014) 0.77
TLR4, IL10RA, and NOD2 mutation in paediatric Crohn's disease patients: an association with Mycobacterium avium subspecies paratuberculosis and TLR4 and IL10RA expression. Med Microbiol Immunol (2013) 0.77
Dysbiosis of the Fecal Microbiota in Cattle Infected with Mycobacterium avium subsp. paratuberculosis. PLoS One (2016) 0.77
Rapid mycobacterial liquid culture-screening method for Mycobacterium avium complex based on secreted antigen-capture enzyme-linked immunosorbent assay. Clin Vaccine Immunol (2009) 0.77
Gut microbiota and IBD: causation or correlation? Nat Rev Gastroenterol Hepatol (2017) 0.77
Role of antibiotics for treatment of inflammatory bowel disease. World J Gastroenterol (2016) 0.76
Detection of Mycobacterium avium subspecies in the gut associated lymphoid tissue of slaughtered rabbits. BMC Vet Res (2015) 0.76
Crohn's disease: evidence for involvement of unregulated transcytosis in disease etio-pathogenesis. World J Gastroenterol (2011) 0.76
Mycobacterium avium subspecies paratuberculosis and Crohn's disease. Lancet Infect Dis (2008) 0.76
Polymorphisms in the gene encoding bovine interleukin-10 receptor alpha are associated with Mycobacterium avium ssp. paratuberculosis infection status. BMC Genet (2010) 0.75
Mycobacterium avium subsp. paratuberculosis (Map) Fatty Acids Profile Is Strain-Dependent and Changes Upon Host Macrophages Infection. Front Cell Infect Microbiol (2017) 0.75
The vesicle-associated function of NOD2 as a link between Crohn's disease and mycobacterial infection. Gut Pathog (2015) 0.75
CD4 T Cell Dependent Colitis Exacerbation Following Re-Exposure of Mycobacterium avium ssp. paratuberculosis. Front Cell Infect Microbiol (2017) 0.75
Virulence and immunogenicity of genetically defined human and porcine isolates of M. avium subsp. hominissuis in an experimental mouse infection. PLoS One (2017) 0.75
A Potential Role of Salmonella Infection in the Onset of Inflammatory Bowel Diseases. Front Immunol (2017) 0.75
Comparison of fecal culture and F57 real-time polymerase chain reaction for the detection of Mycobacterium avium subspecies paratuberculosis in Swiss cattle herds with a history of paratuberculosis. Acta Vet Scand (2014) 0.75
Alteration of GI symptoms in a cow with Johne disease by the dietary organosulfur, 2-mercaptoethanol. Virulence (2012) 0.75
Mycobacterium paratuberculosis as a cause of Crohn's disease. Expert Rev Gastroenterol Hepatol (2015) 0.75
Mycobacterium avium subsp. paratuberculosis and associated risk factors for inflammatory bowel disease in Iranian patients. Gut Pathog (2017) 0.75
Microbiome Changes during Tuberculosis and Antituberculous Therapy. Clin Microbiol Rev (2016) 0.75
A Potential 'Curative' Modality for Crohn's Disease---Modeled after Prophylaxis of Bovine Johne's Disease. Mycobact Dis (2012) 0.75
Environmental influences on the onset and clinical course of Crohn's disease-part 2: infections and medication use. Gastroenterol Hepatol (N Y) (2013) 0.75
Escherichia coli-host macrophage interactions in the pathogenesis of inflammatory bowel disease. World J Gastroenterol (2014) 0.75
Suspected intestinal tuberculosis might be Crohn's disease. Case Rep Med (2010) 0.75
The Consensus from the Mycobacterium avium ssp. paratuberculosis (MAP) Conference 2017. Front Public Health (2017) 0.75
Draft Genome Sequence of a Rare Pigmented Mycobacterium avium subsp. paratuberculosis Type C Strain. Genome Announc (2017) 0.75
Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet (2006) 31.79
CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ (2010) 28.70
Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet (2008) 20.62
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet (2007) 20.57
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ (2007) 14.52
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol (2008) 14.36
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet (2009) 14.01
Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS (2009) 11.62
Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (2008) 11.08
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med (2007) 10.43
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet (2004) 9.88
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med (2007) 8.77
Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet (2004) 8.77
Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ (2008) 8.70
Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One (2009) 8.58
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med (2007) 8.46
Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of homoeopathy and allopathy. Lancet (2005) 7.89
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med (2007) 7.87
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology (2010) 7.86
CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol (2010) 7.04
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet (2009) 6.92
Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ (2011) 6.89
Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet (2005) 6.60
Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet (2010) 6.02
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology (2007) 5.77
A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med (2006) 5.43
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Bull World Health Organ (2007) 5.38
Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health (2008) 5.32
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiology (2007) 5.12
HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet (2006) 5.00
Home visits to prevent nursing home admission and functional decline in elderly people: systematic review and meta-regression analysis. JAMA (2002) 4.75
Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007. AIDS (2010) 4.68
Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis (2010) 4.56
Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ (2009) 4.38
Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration. J Womens Health (Larchmt) (2008) 4.38
Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis (2011) 4.31
Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS (2007) 4.31
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Prev Med (2007) 4.29
Improved effectiveness of partner notification for patients with sexually transmitted infections: systematic review. BMJ (2007) 4.12
What is newsworthy? Longitudinal study of the reporting of medical research in two British newspapers. BMJ (2002) 4.05
Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet (2004) 3.96
Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test. J Clin Epidemiol (2004) 3.93
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol (2009) 3.91
Electronic medical record systems, data quality and loss to follow-up: survey of antiretroviral therapy programmes in resource-limited settings. Bull World Health Organ (2008) 3.85
Direction and impact of language bias in meta-analyses of controlled trials: empirical study. Int J Epidemiol (2002) 3.79
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol (2009) 3.61
Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med (2005) 3.60
Quality of reporting of randomized trials as a measure of methodologic quality. JAMA (2002) 3.60
Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis (2005) 3.57
CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Int J Surg (2011) 3.57
Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. PLoS Med (2008) 3.56
Loss to programme between HIV diagnosis and initiation of antiretroviral therapy in sub-Saharan Africa: systematic review and meta-analysis. Trop Med Int Health (2012) 3.43
Mortality of HIV-infected patients starting antiretroviral therapy in sub-Saharan Africa: comparison with HIV-unrelated mortality. PLoS Med (2009) 3.42
CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med (2003) 3.41
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet (2002) 3.32
Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS (2008) 3.31
Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther (2007) 3.27
A unification of models for meta-analysis of diagnostic accuracy studies. Biostatistics (2006) 3.23
Efficacy and safety of intraarticular hylan or hyaluronic acids for osteoarthritis of the knee: a randomized controlled trial. Arthritis Rheum (2007) 3.22
Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J Clin Microbiol (2006) 3.22
Cohort Profile: Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohorts. Int J Epidemiol (2005) 3.19
Statistical methods for assessing the influence of study characteristics on treatment effects in 'meta-epidemiological' research. Stat Med (2002) 3.16
Meta-analysis: accuracy of rapid tests for malaria in travelers returning from endemic areas. Ann Intern Med (2005) 3.08
Multicenter evaluation of fully automated BACTEC Mycobacteria Growth Indicator Tube 960 system for susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol (2002) 3.06
Missed opportunities to prevent mother-to-child-transmission: systematic review and meta-analysis. AIDS (2012) 3.05
Cohort profile: the Swiss HIV Cohort study. Int J Epidemiol (2009) 3.05
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol (2012) 3.02
Effectiveness of chlamydia screening: systematic review. Int J Epidemiol (2008) 3.00
Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy. Trop Med Int Health (2009) 2.99
Outcomes of the South African National Antiretroviral Treatment Programme for children: the IeDEA Southern Africa collaboration. S Afr Med J (2009) 2.97
Accuracy of magnetic resonance imaging for the diagnosis of multiple sclerosis: systematic review. BMJ (2006) 2.95
Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics (2005) 2.94
Childhood cancer and nuclear power plants in Switzerland: a census-based cohort study. Int J Epidemiol (2011) 2.93
Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis (2006) 2.93
Accuracy of electrocardiography in diagnosis of left ventricular hypertrophy in arterial hypertension: systematic review. BMJ (2007) 2.93
Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. BMJ (2010) 2.88
Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. Am Heart J (2006) 2.87
Domains of physical activity and all-cause mortality: systematic review and dose-response meta-analysis of cohort studies. Int J Epidemiol (2011) 2.83
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol (2011) 2.80
Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr (2014) 2.79
Women's perception of the benefits of mammography screening: population-based survey in four countries. Int J Epidemiol (2003) 2.79
Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS (2009) 2.75
Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration. J Acquir Immune Defic Syndr (2007) 2.71
Publication and non-publication of clinical trials: longitudinal study of applications submitted to a research ethics committee. Swiss Med Wkly (2008) 2.69
Outcomes in patients waiting for antiretroviral treatment in the Free State Province, South Africa: prospective linkage study. AIDS (2010) 2.66
Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLoS Med (2013) 2.60
Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis (2005) 2.58
A systematic review of the survival and complication rates of fixed partial dentures (FPDs) after an observation period of at least 5 years. II. Combined tooth--implant-supported FPDs. Clin Oral Implants Res (2004) 2.57
When one depends on the other: reporting of interaction in case-control and cohort studies. Epidemiology (2009) 2.54
Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev (2011) 2.52
Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clin Infect Dis (2007) 2.51
Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol (2009) 2.51
Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies. Sex Transm Infect (2008) 2.49